Collegium Pharmaceutical, Inc. (COLL) Guidance & Earnings Results

On 2026-08-06 Collegium Pharmaceutical, Inc. mixed guidance: "FY26 Product Revenues Net lowered to $825-855M from $865-895M; JORNAY PM unchanged $190-200M; AZSTARYS raised to $65-75M from $60-70M; Adj EBITDA lowered to $445-470M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

COLLCollegium Pharmaceutical, Inc.Follow COLL — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 747.5M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Mixed	FY26 Product Revenues Net lowered to $825-855M from $865-895M; JORNAY PM unchanged $190-200M; AZSTARYS raised to $65-75M from $60-70M; Adj EBITDA lowered to $445-470M from $475-500M. · full year
7 May 26	Reaffirmed	Product Revenues $805-$825M, JORNAY PM $190-$200M, Adjusted EBITDA $455-$475M · full year
26 Feb 26	Reaffirmed	Product Revenues, Net $805-825M; Jornay PM $190-200M; Adjusted EBITDA $455-475M · full year
6 Nov 25	Raised	Revenue raised to $775-$785M; Adjusted EBITDA raised to $460-$470M · full year
7 Aug 25	Raised	FY2025 revenue raised to $745-760M from $735-750M; FY2025 adjusted EBITDA raised to $440-455M from $435-450M; FY2025 Jornay PM revenue raised to $140-145M from at least $135M · full year

Collegium Pharmaceutical, Inc. — questions

What guidance did Collegium Pharmaceutical, Inc. give?: On 2026-08-06: "FY26 Product Revenues Net lowered to $825-855M from $865-895M; JORNAY PM unchanged $190-200M; AZSTARYS raised to $65-75M from $60-70M; Adj EBITDA lowered to $445-470M from $475-500M."
When does Collegium Pharmaceutical, Inc. report earnings?: Collegium Pharmaceutical, Inc.'s next earnings report is expected on 2026-11-05.

Every figure on this page comes from Collegium Pharmaceutical, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.